ImmunityBio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on the stock and has a $15.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andres Y. Maldonado has given his Buy rating due to a combination of factors linked to ANKTIVA’s commercial and strategic progress. He sees ImmunityBio moving beyond a single U.S. bladder cancer launch into a global immunotherapy platform, underpinned by strong 2025 revenue of $113M, robust sequential growth, and increasing physician adoption and repeat use in the U.S. market.
Maldonado also emphasizes the significance of expanding international approvals, including broad authorization across 33 countries and conditional EU clearance supported by a commercial partnership with Accord Healthcare. In addition, early validation of ANKTIVA in indications beyond bladder cancer, ongoing late-stage trials, and its central role in a wider immunotherapy ecosystem combining NK cells and DNA vaccines support his view of a durable, multi-indication growth story that justifies a Buy rating and $15 price target.
In another report released on February 26, TipRanks – Google also reiterated a Buy rating on the stock with a $10.50 price target.